Compare EFOR & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EFOR | CSTL |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | 2800 | N/A |
| Industry | Professional Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 749.5M | 722.8M |
| IPO Year | N/A | 2019 |
| Metric | EFOR | CSTL |
|---|---|---|
| Price | $20.74 | $25.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $45.50 |
| AVG Volume (30 Days) | ★ 1.0M | 302.5K |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $344,229,000.00 |
| Revenue This Year | N/A | $2.42 |
| Revenue Next Year | N/A | $12.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $16.90 | $14.59 |
| 52 Week High | $21.37 | $44.28 |
| Indicator | EFOR | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 62.65 | 62.17 |
| Support Level | $17.10 | $24.89 |
| Resistance Level | $21.37 | $25.63 |
| Average True Range (ATR) | 1.19 | 1.04 |
| MACD | 0.28 | 0.07 |
| Stochastic Oscillator | 90.49 | 84.83 |
Everforth Inc is a technology and digital engineering company that helps organizations adapt, innovate, and thrive in a world of constant change. It has six solution areas: AI & data, cloud and infrastructure, digital engineering, customer experience, cybersecurity, and enterprise platforms - accelerate time to value for commercial and federal clients.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.